Mirati Therapeutics, Inc.

NasdaqGS:MRTX Stock Report

Market Cap: US$4.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Mirati Therapeutics Management

Management criteria checks 4/4

Mirati Therapeutics' CEO is Chuck Baum, appointed in Nov 2012, has a tenure of 11.17 years. total yearly compensation is $7.42M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $6.57M. The average tenure of the management team and the board of directors is 2.5 years and 5.1 years respectively.

Key information

Chuck Baum

Chief executive officer

US$7.4m

Total compensation

CEO salary percentage9.2%
CEO tenure11.2yrs
CEO ownership0.2%
Management average tenure2.5yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09
Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11
Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Sep 08

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Aug 31

Mirati gains as Amgen posts new combination data for rival cancer drug

Aug 08

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

CEO Compensation Analysis

How has Chuck Baum's remuneration changed compared to Mirati Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$726m

Jun 30 2023n/an/a

-US$738m

Mar 31 2023n/an/a

-US$737m

Dec 31 2022US$7mUS$685k

-US$741m

Sep 30 2022n/an/a

-US$738m

Jun 30 2022n/an/a

-US$645m

Mar 31 2022n/an/a

-US$634m

Dec 31 2021US$18mUS$662k

-US$582m

Sep 30 2021n/an/a

-US$483m

Jun 30 2021n/an/a

-US$491m

Mar 31 2021n/an/a

-US$407m

Dec 31 2020US$12mUS$615k

-US$358m

Sep 30 2020n/an/a

-US$329m

Jun 30 2020n/an/a

-US$296m

Mar 31 2020n/an/a

-US$259m

Dec 31 2019US$8mUS$597k

-US$213m

Sep 30 2019n/an/a

-US$169m

Jun 30 2019n/an/a

-US$142m

Mar 31 2019n/an/a

-US$125m

Dec 31 2018US$5mUS$580k

-US$98m

Sep 30 2018n/an/a

-US$88m

Jun 30 2018n/an/a

-US$77m

Mar 31 2018n/an/a

-US$67m

Dec 31 2017US$2mUS$563k

-US$70m

Compensation vs Market: Chuck's total compensation ($USD7.42M) is about average for companies of similar size in the US market ($USD6.39M).

Compensation vs Earnings: Chuck's compensation has been consistent with company performance over the past year.

CEO

Chuck Baum (65 yo)

11.2yrs

Tenure

US$7,420,213

Compensation

Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...

Leadership Team

NamePositionTenureCompensationOwnership
Charles Baum
Founder11.2yrsUS$7.42m0.16%
$ 6.6m
James Christensen
Executive VP & Chief Scientific Officer10yrsUS$5.01m0.082%
$ 3.4m
Alan Bart Sandler
Executive VP & Chief Medical Officer1.2yrsUS$5.30m0.014%
$ 587.2k
Aaron Ondrey
Chief Financial Officerless than a yearno data0.056%
$ 2.3m
Betsy Gelfand
Chief Accounting Officerless than a yearno datano data
John Moriarty
Chief Legal Officer & Corporate Secretaryless than a yearno datano data
Peter Lee
Chief Compliance Officer2yrsno datano data
Michael Paolucci
Chief People Officer2yrsno datano data
Benjamin Hickey
Chief Commercial Officer4yrsUS$6.93m0.040%
$ 1.6m
Kelly Covello
VP & Head of Medical Affairs3.8yrsno datano data
Ryan Asay
VP & Head of Corporate Affairs3.8yrsno datano data
Susan Welsh
Senior VP of Pharmacovigilance & Chief Safety Officer3yrsno datano data

2.5yrs

Average Tenure

55yo

Average Age

Experienced Management: MRTX's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Charles Baum
Founder11.2yrsUS$7.42m0.16%
$ 6.6m
Bruce Leonard Carter
Independent Director7.3yrsUS$700.41k0.0086%
$ 353.3k
George Demetri
Member of Scientific Advisory Boardno datano datano data
Faheem Hasnain
Chairman & Lead Independent Director4.9yrsUS$979.79k0.012%
$ 511.8k
Julie Michele Cherrington
Independent Director4.6yrsUS$697.91k0%
$ 0
Stephen Baylin
Member of Scientific Advisory Boardno datano datano data
Lillian Siu
Member of Scientific Advisory Boardno datano datano data
Aaron Davis
Independent Director5.1yrsUS$677.91k0.061%
$ 2.5m
Pasi Antero Janne
Member of Scientific Advisory Board5yrsno datano data
Craig Johnson
Independent Director10.3yrsUS$702.91k0.0086%
$ 353.3k
Channing Der
Member of Scientific Advisory Board5yrsno datano data
Maria Martinez-Davis
Independent Director5.1yrsUS$695.41k0.0086%
$ 353.3k

5.1yrs

Average Tenure

65yo

Average Age

Experienced Board: MRTX's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/23 00:57
End of Day Share Price 2024/01/22 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mirati Therapeutics, Inc. is covered by 31 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
George FarmerBMO Capital Markets Equity Research
Jason Matthew GerberryBofA Global Research